{
    "clinical_study": {
        "@rank": "85681", 
        "arm_group": [
            {
                "arm_group_label": "LX4211 Low Dose", 
                "arm_group_type": "Experimental", 
                "description": "400 mg of LX4211 administered once daily for 10 consecutive days"
            }, 
            {
                "arm_group_label": "LX4211 High Dose", 
                "arm_group_type": "Experimental", 
                "description": "800 mg of LX4211 administered once daily for 10 consecutive days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Identical placebo administered once daily for 10 consecutive days"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the safety and tolerability of multiple\n      oral doses of LX4211 400 mg and LX4211 800 mg (administered once daily for 10 consecutive\n      days) in healthy subjects."
        }, 
        "brief_title": "Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult subjects \u2265 18 to \u2264 55 years of age\n\n          -  Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm\n             Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm\n\n          -  Body mass index (BMI) \u226518 and \u226435 kg/sq m\n\n          -  Willing and able to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Use of any medication (prescription, over-the-counter, herbal tea, or supplements)\n             within 5 days of dosing\n\n          -  Use of any investigational agent or study treatment within 30 days of dosing\n\n          -  Use of any protein or antibody-based therapeutic agents within 3 months of Screening\n\n          -  Prior exposure to LX4211\n\n          -  Use of cigarettes or any tobacco products within 2 months prior to Screening and\n             while participating in the study\n\n          -  History of bariatric surgery or any other gastrointestinal surgery that may induce\n             malabsorption\n\n          -  History of any major surgery within 6 months of Screening\n\n          -  History of any hypersensitivity to the inactive components of LX4211\n\n          -  History of renal disease or significantly abnormal kidney function tests\n\n          -  History of hepatic disease or significantly abnormal liver function tests\n\n          -  History of any active infection within 14 days prior to Day 1\n\n          -  History of alcohol or substance abuse within 2 years prior to Day 1\n\n          -  Donation or loss of >400 mL of blood or blood product within 3 months of dosing\n\n          -  Positive urine glucose at Screening\n\n          -  Positive urine screen for drugs of abuse, or urine test for alcohol at Screening or\n             Day -1\n\n          -  Inability or difficulty swallowing pills\n\n          -  Unable or unwilling to communicate or cooperate with the Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916850", 
            "org_study_id": "LX4211.1-110-NRM", 
            "secondary_id": "LX4211.110"
        }, 
        "intervention": [
            {
                "arm_group_label": "LX4211 Low Dose", 
                "intervention_name": "LX4211 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LX4211 High Dose", 
                "intervention_name": "LX4211 800 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "LX4211 Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas"
                }, 
                "name": "Lexicon Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1b, Single-center, Double-blind, Randomized, Placebo-controlled Study on the Safety, Tolerability, and Pharmacokinetic Effects of Multiple Doses of LX4211 400 mg qd and LX4211 800 mg qd in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Lexicon Pharmaceuticals, Inc.", 
            "last_name": "Ikenna (Ike) Ogbaa, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 10"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916850"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area under the curve", 
            "safety_issue": "No", 
            "time_frame": "Days 1 through 10"
        }, 
        "source": "Lexicon Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lexicon Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}